Skip to main content
. Author manuscript; available in PMC: 2017 Jan 30.
Published in final edited form as: Clin Cancer Res. 2016 Feb 8;22(15):3746–3754. doi: 10.1158/1078-0432.CCR-15-2781

Figure 2.

Figure 2

Mutational profiling of CMML patients treated with ruxolitinib. A, the mutational landscape of CMML patients on trial. Patients are represented in columns and gene mutations in rows. Cases sorted by combined MDS IWG 2006 and spleen response. The number of mutations seen in the entire cohort is denoted in the bar plot (L). B–D, sequential variant allele frequency of responding patients from 0 to 1.00. E–J, sequential variant allele frequency of nonresponding patients. x-axis denotes week (W) and/or best response (BR).